Analyst: James Altenbach

Analyst

James Altenbach, CFA is a Portfolio Analyst. He joined DFPG Investments in 2019. Previously, he was an investment advisory professional at Penniall Associates. Prior to that, he had been Principal of Florentez Investment Management, an ETF sponsor. Since the firm’s inception, he served as an advisor to the President on strategic matters including research and proprietary analysis and product development on ETFs. Prior to that Altenbach was an equity research analyst with RedChip Companies. He did his undergraduate work in business administration (Finance) at California State University, Los Angeles, with distinction, and holds the designation of Chartered Financial Analyst (CFA).

Biography

Analyst: John Chambers

Analyst

John Chambers joins H. C. Wainwright & Co. from Roth Capital Partners where he had been Vice Chairman and Head of Healthcare Investment Banking. In his 28-year career, Mr. Chambers has played a senior role in the Life Sciences/Healthcare Investment Banking groups at Rodman & Renshaw, Cowen, Lehman Brothers and UBS Securities.

Continue reading “Analyst: John Chambers”

Analyst: Swayampakula Ramakanth, Ph.D.

Analyst

Dr. Swayampakula Ramakanth is a Managing Director of Equity Research at H.C. Wainwright whose research focuses on the healthcare sector. Dr. Ramakanth’s research covers companies operating in oncology, wound health, medical devices, spine health and animal health. Dr. Ramakanth possesses over ten years of experience as a Life Sciences Equity Analyst as well as seven years of biotechnology industry experience. Prior to joining H.C. Wainwright, Dr. Ramakanth worked as a Junior Analyst at both Jefferies and Merrill Lynch covering large cap pharmaceuticals.

Continue reading “Analyst: Swayampakula Ramakanth, Ph.D.”

Analyst: Edward White

Analyst

Edward White is a Managing Director of Equity Research at H.C. Wainwright whose research focuses on both the biotechnology and the specialty pharmaceutical sectors. Mr. White’s expertise covers companies operating in the oncology, immune-oncology, infectious disease, and gastrointestinal sectors. Prior to working at H.C. Wainwright, Mr. White has worked as a Wall Street Healthcare Analyst, on both the buy-side and the sell-side, since 1996. Mr. White’s previous sell-side experience includes working for Fahnestock & Company (now Oppenheimer), Gerard, Klauer, Mattison & Company (now BMO Capital Markets), Deutsche Bank Securities, and a couple of boutique firms.

Continue reading “Analyst: Edward White”

Analyst: Doug Tsao

Analyst

Doug Tsao is a Managing Director of Equity Research at H.C. Wainwright whose research focuses on Biopharmaceuticals and Specialty Pharmaceuticals.  Specific therapeutics areas include Endocrinology, Metabolic disease, Dermatology, and CNS in addition to other areas. Prior to joining H.C. Wainwright, Mr. Tsao was a senior equity research analyst at Barclays covering U.S. Specialty Pharmaceutical companies as well as small and midcap medical device companies.

Continue reading “Analyst: Doug Tsao”

Analyst: Raghuram Selvaraju Ph.D.

Analyst

Dr. Raghuram Selvaraju is a Managing Director of Equity Research at H.C. Wainwright whose research focuses on the healthcare sector. Dr. Selvaraju possesses over a decade’s worth of experience in Healthcare Equity Research. Dr. Selvaraju was ranked by both the StarMine for his earnings accuracy and by The Wall Street journal’s annual Best on the Street Analyst for his stock-picking performance. In addition, Dr. Selvaraju has appeared numerous times on Bloomberg, CNBC, Business News Network and BTV where he discussed drug development trends, healthcare reform policy, and pharma and biotech M&A.

Continue reading “Analyst: Raghuram Selvaraju Ph.D.”

Analyst: Joseph Pantginis, Ph.D.

Analyst

Dr. Joseph Pantginis is a Managing Director of Equity Research at H.C. Wainwright whose research focuses on the healthcare sector. Dr. Pantginis conducted more than seventeen years of healthcare equity research. Prior to joining H.C. Wainwright, Dr. Pantginis worked as a Senior Research Analyst and Head of Biotechnology Research at ROTH Capital Partners. Dr. Pantginis also held senior positions at Merriman, Canaccord Adams, Commerce Capital Markets, JBHanauer and Ladenburg. Prior to his equity research career, Dr. Pantginis worked at Regeneron Pharmaceuticals, where he founded the Retroviral Core Facility.

Continue reading “Analyst: Joseph Pantginis, Ph.D.”

Analyst: Oren G. Livnat

Analyst

Oren G. Livnat is a Managing Director of Equity Research at H.C. Wainwright whose research focuses on the specialty pharmaceutical industry. Mr. Livnat conducted more than twelve years of research on both the sell-side and the buy-side. Prior to joining H.C. Wainwright, Mr. Livnat worked as a Senior Analyst covering specialty and generic pharma at Iguana Healthcare Partners, a dedicated healthcare long/short hedge fund. Mr. Livnat began his career as an Associate at Natixis Bleichroeder and successively worked as a Senior Analyst at JMP Securities covering both commercial and development-stage companies.

Continue reading “Analyst: Oren G. Livnat”

Analyst: Heiko Ihle

Analyst

Heiko Ihle is a Managing Director of Equity Research at H.C. Wainwright whose research focuses on companies in the Metals and Mining industry. Prior to joining H.C. Wainwright, Mr. Ihle worked as a Senior Research Analyst at Euro Pacific Capital where his research was also focused on the Mining industry. Prior to that, Mr. Ihle worked at Gabelli & Company covering both the Industrials and E&C industries. Mr. Ihle also completed summer internships with Deutsche Bank on the foreign exchange trading desk and on fixed income sales, in New York and Germany, respectively.

Continue reading “Analyst: Heiko Ihle”